Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
|Videos|March 16, 2016
New and Emerging Therapies to Treat Heart Failure
Sneha Srivastava, PharmD, BCACP, discusses the new and emerging therapies to treat heart failure.
Advertisement
Sneha Srivastava, PharmD, BCACP, discusses the new and emerging therapies to treat heart failure.
This video was recorded at the Directions in Pharmacy 6th Annual CE Conference in Plainsboro, NJ.
Advertisement
Related to this article
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5